Cablivi
PreclinicalSmall molecule
Cablivi is one of 17 small molecule programs targeting Thrombotic Thrombocytopenic Purpura. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Thrombotic Thrombocytopenic Purpura
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Medrol
PfizerApproved
Neoral
NovartisPhase 3
Rayos
RRoxane Laboratories
Phase 3
Rituxan
RochePhase 2
Plasma Exchange
SanofiPhase 3
Danocrine
SanofiPhase 2
Vyvgart
ArgenxPhase 2
Immunosuppressive Treatment
SanofiPhase 3
Anti-CD20 Antibody
SanofiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cablivi. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Cologne